This inventor holds 4 USPTO granted patents and 4 EPO patents. Top assignee: Council of Scientific and Industrial Research. Active years: 2012-2014.
Location History:
- Andhra Pradesh, IN (2013)
- Hyderabad, IN (2012 - 2014)
Company Filing History:
Years Active: 2012-2014
Title: Balakishan Gorre: Innovator in Anticancer Research
Introduction
Balakishan Gorre is a prominent inventor based in Hyderabad, Telangana, India. He has made significant contributions to the field of medicinal chemistry, particularly in the development of potential anticancer agents. With a total of 4 patents to his name, Gorre is recognized for his innovative approaches to combating cancer.
Latest Patents
Gorre's latest patents include groundbreaking work on Imidazolone-chalcone derivatives as potential anticancer agents. This invention provides chalcone-linked imidazolone compounds that have shown efficacy against fifty-three human cancer cell lines. Another notable patent involves Cinnamido-pyrrolo[2,1-C][1,4]benzodiazepines, which are also being explored as potential antitumor agents. This invention outlines a process for the preparation of these compounds, which have demonstrated promise against various human cancer cell lines.
Career Highlights
Balakishan Gorre is affiliated with the Council of Scientific and Industrial Research, where he continues to advance his research in medicinal chemistry. His work is characterized by a commitment to developing effective treatments for cancer, showcasing his dedication to improving healthcare outcomes.
Collaborations
Gorre has collaborated with notable colleagues such as Kamal Ahmed and Sreekanth Kokkonda. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions in the fight against cancer.
Conclusion
Balakishan Gorre's contributions to anticancer research through his patents and collaborations highlight his role as a key innovator in the field. His work not only advances scientific knowledge but also holds the potential to impact cancer treatment significantly.
